The early breast cancer (EBC) biological characteristics from NEMESI, an Italian retrospective, observational study. Background: Among HER2 overexpressing breast cancers, chromosome 17 polysomy (C17) ...

Polysomy 17 affects HER-2 testing in breast cancer and is a major cause of equivocal results by FISH. We show that tumors displaying polysomy 17 in the absence of HER2 gene amplification resemble more ...

December 22, 2008 — The search for biomarkers that would predict a response to anthracycline therapy in breast cancer has homed in on a new promising target, while discarding 2 previous contenders.

The overexpressed protein is the therapeutic target for treatment with humanized monoclonal antibody, trastuzumab. 10, 11 Trastuzumab has been demonstrated to be effective in the treatment of breast ...

HER-2/neu oncoprotein, also known as erbB-2, is overexpressed in approximately 20–30% breast cancers (1, 2, 3). Laboratory assessment of HER-2/neu status has become a critical step in determining the ...